New Hope for Hidradenitis Suppurativa Patients: Ozempic May Improve Condition
Add this common skin condition to the list of ailments that Ozempic may improve.
Hidradenitis Suppurativa: A Chronic Condition Affecting Millions
Hidradenitis suppurativa (HS) is a lesion-causing inflammatory disorder that affects at least 1 in 100 people and is strongly associated with obesity.
Ozempic Shows Promise in Managing Hidradenitis Suppurativa
New research finds that semaglutide, the active ingredient in Ozempic and Wegovy, may help manage the skin condition hidradenitis suppurativa.
In a new study, 30 obese patients with varying levels of HS received semaglutide weekly for about eight months.
Participants lost 13 pounds on average, improved their blood sugar, reduced inflammation in their body, and experienced fewer HS flare-ups.
Notable Improvements
On average, the frequency of these episodes went from once every 8 ½ weeks to once every 12 weeks.
Experts Hope for Further Research
“Our findings suggest that semaglutide, even at modest doses, can offer substantial benefits in managing HS,” said Dr. Daniel Lyons, lead researcher from St. Vincent’s University Hospital in Dublin, Ireland.
“While the drug’s role in promoting weight loss is well-established, what’s particularly exciting is its potential to also reduce the frequency of HS flare-ups, contributing to the notable improvements observed in patients’ quality of life,” Lyons added.
Conclusion
Ozempic may offer a new hope for hidradenitis suppurativa patients, reducing the frequency of flare-ups and improving their quality of life. Further research is needed to confirm these findings and assess the effect of higher doses of semaglutide.
FAQs
What is hidradenitis suppurativa?
Hidradenitis suppurativa is a lesion-causing inflammatory disorder that affects at least 1 in 100 people and is strongly associated with obesity.
What is Ozempic?
Ozempic is a medication approved by the US Food and Drug Administration to treat Type 2 diabetes in adults and Wegovy in 2021 for adult weight loss.
How did the study work?
In the study, 30 obese patients with varying levels of HS received semaglutide weekly for about eight months, resulting in notable improvements in their condition.
What are the next steps?
Further research is needed to confirm these findings and assess the effect of higher doses of semaglutide.
